|
Unit：
|
|
|
|
Project Area：
|
|
|
|
Industry：
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode：
|
Collaborate
|
|
|
Nature of Project：
|
Encourage
|
|
|
Working Progress in Prior Period：
|
||
|
Total Investment：
|
discussed in detai
|
|
|
Expected to Attract Investment：
|
面谈 ten thousand RMB
|
|
Biological & New Pharmaceutical Industry
In 2020, the added value of industrial enterprises above designated size rose by 0.3 percent year on year, and the output value of the industry exceeded RMB 60 billion. The technology of such protein drugs as recombinant human granulocyte-macrophage colony-stimulating factor and its market share took the lead in China. In addition, bio-pharmaceutical technologies such as an Escherichia coli-derived virus-like particle-based vaccine, a recombinant hepatitis E vaccine, and a recombinant human papillomavirus vaccine all held world leading positions.
Invest Fujian is a professional website to provide Invest Fujian policy, guide and service for foreign investor.
-
Address：
Floor 5，No.3 Building，No. 118 Tongpan Road，Gulou District，Fuzhou，China
-
Tel：
+86-591-87810615
-
Fax：
+86-591-83839780
-
Email：
tczx2@swt.fujian.gov.cn
- Sponsor： Fujian Provincial Department of Commerce
- Organizer： Fujian Investment Promotion Center
- Copyright： Invest Fujian,China 闽ICP备14009608号-12
